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Milan, ItalyOBJECTIVES The goal of this study was to determine the long-term prognostic value of coronary
computed tomography angiography (CTA) in a large coronary artery bypass graft (CABG) population.
BACKGROUND Coronary CTA has shown prognostic utility in patients without previous revascular-
ization. However, prognostication with coronary CTA in CABG patients has not been fully assessed.
METHODS Between March 2005 and April 2009, 887 consecutive CABG patients (mean age 66.8 
8.4 years) were considered for the inclusion in the study. Patients were classiﬁed by the number of un-
protected coronary territories (UCTs) and a summary of native vessel disease and graft patency: the cor-
onary artery protection score (CAPS). A primary endpoint (cardiovascular [CV] death, nonfatal myocardial
infarction [MI]) and a secondary combined adverse events endpoint (CV death, MI, unstable angina, and
late revascularizations) were recorded.
RESULTS Among the 887 evaluated, 166 did not meet the inclusion criteria. The ﬁnal study popula-
tion consisted of 721 subjects. Ten patients were excluded for unevaluable coronary CTA images. Of the
remaining 711 patients, follow-up (mean 73.5  14 months) was obtained in 698. Three hundred forty-
seven events were recorded. By univariable analysis, the strongest coronary CTA predictors of events
were UCT 2 and 3 (hazard ratio [HR] for CV death/MI: 7.5 and 10.19, p < 0.0001 and p < 0.0003, respec-
tively) and CAPS 4 (HR for CV death/MI: 24.1, p < 0.0001). A high number of UCTs was also a strong multi-
variable independent predictor of CV death/MI (HR: 7.78 and 10.18 for UCT 2 and 3, p < 0.0001 and
p < 0.0007, respectively). Cumulative survival rates for CV death/MI and composite adverse CV events
were 86% and 73% with UCT 0, 84% and 49% with UCT 1, 53% and 3% with UCT 2, and 29% and 0%
with UCT 3, respectively.
CONCLUSIONS Coronary CTA appears to be a promising tool for long-term risk stratiﬁcation of
CABG patients. The UCT score has signiﬁcant prognostic value to predict CV deaths/MI. (J Am Coll
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581oronary computed tomography angiography
(CTA) is a noninvasive diagnostic tool
useful for the detection of obstructive cor-
onary artery disease (CAD) and assessment
of coronary artery bypass grafts (CABG) (1–3). The
method demonstrated signiﬁcant prognostic value
in patients with suspected CAD, predicting all-
cause mortality and major adverse cardiac events
(4–6). However, the prognostic utility of coronary
CTA in CABG patients has been investigated bySee page 590
A B B R E V I A T I O N S
A N D A C R O N YM S
AUC = area under the curve
CABG = coronary artery bypass
grafts
CAD = coronary artery disease
CAPS = coronary artery
protection score




HR = hazard ratio
ICA = invasive coronary
angiography
LAD = left anterior descending
coronary artery
LCx = left circumﬂex coronary
artery
MI = myocardial infarction
NRI = net reclassiﬁcation
improvement
UCT = unprotected coronary
territory2 studies only, both with a follow-up no longer than
20 months, and in 1 case, enrolling a relatively small
(250 patients) population. Nevertheless, they sug-
gested that anatomic data provided by coronary
CTA may help in determining the prognosis of
patients after CABG (7,8). Indeed, previous
studies using invasive coronary angiography
(ICA) demonstrated that the completeness of
revascularization is an important predictor of
outcome and that the number of diseased arterial
territories lacking a patent graft is a key determinant
of mortality (9). Therefore, the objective of the
present study was to evaluate the incremental
prognostic value of coronary CTA in a large pop-
ulation of CABG patients undergoing long-term
follow-up.
METHODS
Patient population. Between March 2005 and April
2009, 887 consecutive patients with a history of
previous CABG undergoing coronary CTA were
prospectively enrolled in our study. Indications for
coronary CTA were chest pain, dyspnea, and
equivocal or abnormal stress test. One-hundred
forty-ﬁve patients were excluded because of
abnormal (<55%) left ventricular ejection fraction
(n ¼ 30), prior PCI/stent procedure (n ¼ 95), or
signiﬁcant valve disease (n ¼ 20). Moreover, a total
of 21 patients were excluded because of contra-
indications to contrast agents (n ¼ 5), impaired
renal function (creatinine clearance <60 ml/min)
(n ¼ 8), inability to sustain a 15-s breath hold (n ¼
3), and arrhythmias (n ¼ 5). Thus, the study pop-
ulation consisted of 721 subjects. The mean time
between previous CABG and coronary CTA
investigation was 72  41 months (range 21 to 139
months, median 61.9 months). The study was
approved by our institution’s scientiﬁc and ethical
committees, and all patients gave written informed
consent. A structured interview and a detailedmedical history were acquired at the time of coro-
nary CTA.
Coronary CTA scan protocol, image reconstruction,
and patient preparation. Metoprolol was adminis-
tered intravenously before coronary CTA with a
titration dose up to 25 mg in patients with heart rate
>65 beats/min. In all patients, coronary CTA was
performed using a 64-slice scanner (LightSpeed
VCT Medical System, GE Healthcare, Milwaukee,
Wisconsin) (64  0.625-mm collimation, 330-ms
gantry rotation time). Dose modulation was
attained with electrocardiographic (ECG) gating
for a maximum gantry delivery between 40%
and 80% during the R-R interval. A bolus of 80 to
110 ml of high-concentration contrast
(Iomeron 400 mg/ml, Bracco, Milan, Italy)
was administered intravenously at 5 ml/s,
followed by 50 ml of saline injected at
the same infusion rate. The scan was
initiated according to the bolus-tracking
technique. Image datasets were analyzed
using multiplanar reconstruction on post-
processing workstations (CardioQ3 pack-
age, Advantage Workstation version 4.2,
GE Healthcare).
Coronary CTA data analysis. All coronary
CTA examinations were evaluated by 2
expert readers unaware of patient clinical
data. In case of disagreement, a joint
reading was performed, and a consensus
decision was reached. Revascularizations
were classiﬁed in terms of the coronary
territories supplied by grafts (left anterior
descending coronary artery [LAD], left
circumﬂex coronary artery [LCx], or right
coronary artery). Two models of CAD
severity were used to assess coronary
CTA prognostic value: unprotected cor-
onary territories (UCTs) and coronary
artery protection score (CAPS). The
UCTs categorized patients according to the number
of vascular territories that were not protected by
grafts (0, 1, 2, or 3) (9). In each patient, 3 coronary
territories, corresponding to the 3 major epicardial
coronary arteries (LAD, LCx, right coronary ar-
tery), and their corresponding branches (diagonal
and marginal arteries) were evaluated. Patients
with obstructive CAD in the diagonal or obtuse
marginal branches were included in the LAD and
LCx obstructive CAD groups, respectively. A cor-
onary territory was deemed unprotected if: 1) an
ungrafted native coronary artery had a signiﬁcant
stenosis; 2) a signiﬁcant stenosis in the native artery
was distal to the graft insertion; or 3) signiﬁcant
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582stenoses were present in both the native artery and
its graft (9). The left main coronary artery was
assigned 2 or 3 coronary territories in a right-
dominant or left-dominant coronary system,
respectively. Similarly, the LCx was assigned 2 cor-
onary territories when the native coronary system
was left dominant. The CAPS combined the
severity of both native coronary and graft disease
(CAPS 1: single-vessel disease  1 protected ter-
ritory; CAPS 2: 2-vessel disease þ 2 protected
territories; CAPS 3: 2-vessel disease þ 1 protected
territory; CAPS 4: 2-vessel disease þ 0 protected
territories; CAPS 5: 3-vessel disease þ 3 protected
territories; CAPS 6: 3-vessel disease þ 2 protected
territories; CAPS 7: 3-vessel disease þ 1 protected
territory; and CAPS 8: 3-vessel disease þ 0 pro-
tected territories) (9). We have grouped CAPS into
4 categories because it seemed some groups had too
few events: CAPS 1, which includes CAPS 1 and 2;
CAPS 2, which includes CAPS 3 and 4; CAPS 3,
which includes CAPS 5 and 6; and CAPS 4, which
includes CAPS 7 and 8.
Follow-up. The follow-up was performed either by
clinical visit or telephone interview by researchers
blinded to coronary CTA and clinical data. Hospital
records were screened for clinical events to conﬁrm
the obtained information. Outcome measures were a
primary endpoint including cardiovascular (CV)
death and nonfatal myocardial infarction (MI), and
a secondary combined adverse events endpoint (CV
death, nonfatal MI, unstable angina requiring hos-
pitalization, and revascularization). The diagnosis of
nonfatal MI was based on the simultaneous pres-
ence of all these criteria: typical chest pain, elevated
cardiac enzymes, and typical ECG changes (10).
Unstable angina was deﬁned as acute chest pain
with or without the presence of ECG abnormalities
and no cardiac enzyme elevation (11). All deaths
were reviewed and classiﬁed as cardiac (death caused
by acute MI, ventricular arrhythmias, or refractory
heart failure) or noncardiac. All revascularizations
were classiﬁed as early (elective revascularization
within 6 months after coronary CTA) or late. Only
late revascularizations were considered as cardiac
events, whereas patients with elective early revas-
cularization were excluded from analysis.
Statistical analysis. Statistical analysis was per-
formed using SAS (version 9.1.3, SAS Institute,
Cary, North Carolina) and SPSS version 13.0
software (SPSS, Chicago, Illinois). Statistical sig-
niﬁcance was deﬁned as p < 0.05. Continuous
variables are presented as mean  SD, and discrete
variables as absolute numbers and percentages.
To compare patient characteristics and coronaryCTA data, chi-square or Fisher exact tests were
used for categorical variables, and Student t test for
continuous variables. All continuous variables were
normally distributed and compared using non-
parametric Mann-Whitney test. To identify the
association between coronary CTA variables and
outcomes, Cox regression analysis was used. First,
univariable analysis of clinical characteristics and
coronary CTA variables was performed to identify
potential predictors. Hazard ratios (HR) were cal-
culated with 95% conﬁdence intervals as an estimate
of the risk associated with a particular variable. To
determine independent predictors of the composite
endpoints, multivariable analysis of coronary CTA
variables with p # 0.05 in univariable analysis was
performed, which was corrected for baseline char-
acteristics (male sex, age, CV risk factors). We
developed 2 different multivariable models for CV
death/MI and combined adverse CV events to
reduce bias introduced by events such as angina or
revascularization. The ﬁrst model was adjusted for
UCTs and clinical baseline characteristics. The
second model was adjusted for CAPS and clinical
baseline characteristics. Cumulative event-free sur-
vival rates as a function over time were obtained by
Kaplan-Meier method. Event-free survival curves
for CV death/MI and composite adverse CV events
were compared using the log-rank test. Area under
the receiver-operating characteristic curve (AUC),
net reclassiﬁcation improvement (NRI), and inte-
grated discrimination improvement were used to
assess the incremental prognostic value of coronary
CTA among post-CABG patients. Moreover, we
analyzed the improvement of the model related to
UCT or CAPS, respectively.
RESULTS
Of the 887 patients prospectively enrolled, 166 were
excluded because they did not meet the inclusion
criteria. Others (10 patients) were excluded because
coronary CTA images were not assessable. Of the
remaining 711 patients, 13 were lost to follow-up,
whereas 698 (98%) had a complete follow-up
(mean 73.5  14 months, up to 87 months). In
them, indications for coronary CTA were chest pain
(24%), dyspnea (29%), and equivocal or abnormal
stress test (47%). In all patients, left ventricular
ejection fraction was $55%. There was no signiﬁ-
cant difference in clinical characteristics and coro-
nary CTA results between patients who underwent
long-term follow-up and those lost to follow-up.
Three hundred forty-seven cardiac events were
recorded. Of them, 49 were CV deaths, 67 nonfatal
















Age 67  8 67  8 66  8 67  9 67  8
Male 577 (83) 262 (83) 315 (83) 63 (87) 514 (82)
BMI, kg/m2 27.2  5.2 28.1  5.6 26.7  5 27.7  5.5 27.1  4.8
Hypercholesterolemia 445 (65) 220 (71) 225 (60)* 45 (62) 400 (64)
Hypertension 518 (75) 239 (77) 279 (75) 147 (77) 371 (75)
Family history of CAD 155 (23) 61 (20) 94 (25) 10 (14) 145 (23)y
Diabetes 174 (25) 90 (29) 84 (22)* 21 (29) 153 (24)
Smoking 211 (31) 88 (29) 123 (33) 16 (22) 195 (31)y
Positive stress test 329 (47) 173 (25) 156 (22) 64 (89) 265 (42)
Medical therapy
Nitrates 318 (47) 178 (59) 140 (38)* 45 (62) 273 (44)y
Beta-blockers 484 (71) 216 (71) 268 (72) 54 (75) 430 (69)
Aspirin 627 (93) 286 (94) 341 (91) 64 (89) 563 (90)y
Calcium channel
blockers
187 (28) 83 (27) 104 (28) 11 (15) 176 (28)y
ACE-inhibitors 299 (44) 137 (45) 162 (43) 36 (50) 263 (42)
AT1 blockers 100 (15) 49 (16) 51 (14) 15 (21) 85 (13)
Diuretics 180 (27) 99 (33) 81 (22)* 32 (44) 148 (24)y
Amiodarone 56 (8) 27 (9) 29 (8) 8 (11) 48 (8)
Statins 448 (66) 203 (67) 245 (66) 40 (55) 408 (66)y
UCT
0 299 (43) 68 (21) 231 (60)* 13 (18) 286 (45)y
1 294 (42) 150 (47) 144 (38) 26 (36) 268 (43)
2 93 (13) 86 (27) 7 (2) 26 (36) 67 (11)
3 12 (2) 12 (4) 0 (0) 11 (15) 1 (1)
CAPS
1 169 (24) 25 (8) 144 (38)* 2 (3) 167 (27)y
2 92 (13) 62 (20) 30 (8)* 8 (11) 84 (13)
3 338 (48) 138 (43) 200 (53)* 30 (41) 308 (49)
4 99 (15) 91 (29) 8 (2)* 32 (44) 67 (11)
Values are mean  SD or n (%). *p < 0.05 versus patients with events. yp < 0.05 versus patients with hard events.
ACE ¼ angiotensin-converting enzyme; AT1 ¼ angiotensin 1 receptor; BMI ¼ body mass index; CAD ¼ coronary artery disease; CAPS ¼ coronary artery protection
score; CTA ¼ computed tomography angiography; CV ¼ cardiovascular; MI ¼ myocardial infarction; UCT ¼ unprotected coronary territory.
Table 2. Coronary CTA Evaluation of CABG Patency
Type of Graft Patent Stenosis £50% Stenosis >50% Occlusion Total
Right-IMA 62 (74.0) 2 (2.0) 0 (0.0) 20 (24.0) 84
Left-IMA 594 (91.0) 1 (0.2) 5 (0.8) 54 (8.0) 654
Radial artery 28 (62.0) 3 (7.0) 2 (4.0) 12 (27.0) 45
Vein graft 565 (63.0) 41 (5.0) 72 (8.0) 218 (24.0) 896
Total 1,249 (74.0) 47 (3.0) 79 (5.0) 304 (18.0) 1,679
Values are n (%) or n.
CABG ¼ coronary artery bypass graft; IMA ¼ internal mammary artery.
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Table 3. Clinical and Coronary CTA Univariable Predictors of Events
Combined Adverse CV Events
HR (95% CI) p Value
CV Death/MI
HR (95% CI) p Value
Clinical characteristics
Age 1.00 (0.99–1.02) 0.33 1.06 (1.03–1.10) <0.0001y
Male 1.01 (0.75–1.36) 0.91 1.44 (0.71–2.89) 0.30
BMI 1.02 (1.01–1.03) 0.23 1.05 (1.01–1.08) 0.12
Hypercholesterolemia 1.47 (1.15–1.88) 0.0018* 1.13 (0.68–1.88) 0.63
Hypertension 1.19 (0.92–1.55) 0.18 1.34 (0.74–2.42) 0.32
Family history of CAD 0.78 (0.59–1.03) 0.08 0.55 (0.28–1.08) 0.08
Diabetes 1.29 (1.01–1.65) 0.03 1.35 (0.80–2.26) 0.25
Smoking 0.79 (0.61–1.01) 0.06 0.59 (0.33–1.04) 0.06
Positive stress test 1.74 (1.04–2.91) 0.03 2.43 (0.97–6.11) 0.05
Medical therapy
Nitrates 1.86 (1.48–2.34) <0.0001* 2.61 (1.57–4.36) 0.0002y
Beta-blockers 0.99 (0.77–1.26) 0.92 1.63 (0.89–2.98) 0.11
Aspirin 1.47 (0.90–2.40) 0.11 2.08 (0.65–6.65) 0.21
Calcium channel blockers 0.97 (0.75–1.25) 0.82 0.46 (0.24–0.88) 0.01
ACE-inhibitors 1.05 (0.84–1.32) 0.64 1.28 (0.96–1.71) 0.08
AT1 blockers 1.20 (0.89–1.64) 0.22 1.57 (0.97–2.54) 0.06
Diuretics 1.50 (1.18–1.91) 0.0009* 2.75 (1.70–4.45) <0.0001y
Amiodarone 1.19 (0.80–1.76) 0.38 1.48 (0.70–3.10) 0.29
Statins 1.03 (0.81–1.31) 0.76 0.71 (0.43–1.16) 0.17
UCT
0 1.00 1.00
1 2.75 (2.06–3.66) <0.0001* 1.24 (0.65–2.35) 0.51
2 8.39 (6.07–11.61) <0.0001* 7.58 (4.02–14.30) <0.0001y
3 8.47 (4.57–15.70) <0.0001* 10.19 (2.9–35.43) 0.0003y
CAPS
1 1.00 1.00
2 6.77 (4.7–10.8) <0.0001* 3.71 (1.11–12.36) 0.03
3 3.09 (2.01–4.73) <0.0001* 3.76 (1.31–10.76) 0.01
4 12.6 (8.1–19.8) <0.0001* 24.12 (8.35–69.65) <0.0001y
*p < 0.05 versus patients with combined adverse CV events. yp < 0.05 versus patients with CV death/MI.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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584MI, 124 unstable angina, and 76 were late revas-
cularizations. Thirty-one patients with early elective
revascularizations were excluded from event-free
survival analysis.
Clinical and coronary CTA data. Table 1 shows
clinical characteristics, coronary CTA results, and
patient outcomes. Prevalence of dyslipidemia and
diabetes was signiﬁcantly higher in patients with
events than in those without events. The rate of
events progressively increased with increasing UCT
score. Particularly, 100% of patients with UCT 3
had events (with a 99% rate of CV death/MI).
Table 2 shows the coronary CTA evaluation ofCABG patency. Notably, 595 of 654 (91%) left
internal mammary arteries were free from signiﬁ-
cant stenosis, whereas 8% and 24% of saphenous
vein grafts showed >50% stenosis or occlusion,
respectively.
Univariable predictors of events. Clinical and cor-
onary CTA univariable predictors of events are re-
ported in Table 3. Signiﬁcant clinical predictors of
events were dyslipidemia and diabetes for combined
adverse CV events, and age, family history of CAD,
and smoking for CV deaths and MI. A positive
stress test had a HR for CV death/MI of 2.43.
Regarding coronary CTA predictors using the UCT
Figure 1. UCT Survival Analysis
Kaplan-Meier curves for cardiovascular (CV) death/myocardial infarction (MI) (A) and for composite adverse CV events (B) in patients with
unprotected coronary territory (UCT) 0, 1, 2, or 3.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 6 , 2 0 1 4 Mushtaq et al.
J U N E 2 0 1 4 : 5 8 0 – 9 Prognostic Value of CTA in CABG Patients
585model, HRs were particularly increased in patients
with UCT 2 (7.58 for CV death/MI and 8.39 for
combined adverse CV events) and UCT 3 (10.19
for CV deaths/MI and 8.47 for combined adverse
CV events). Regarding CAPS, patients with CAPS
4 showed the highest HRs (24.12 and 12.6 for CV
deaths/MI and combined adverse CV events,
respectively).
Survival analysis. Kaplan-Meier survival curves
based on UCT 0 to 3 and CAPS 1 to 4 are shown in
Figures 1 and 2, respectively. Regarding CV death/
MI, the 73-month cumulative event-free survival
rates in patients with UCT 0, 1, 2, and 3 were 86%,
84%, 53%, and 29%, respectively. Including re-
vascularizations and unstable angina, the event-free
survival rates with UCT 0, 1, 2, and 3 were 73%,
49%, 3%, and 0%, respectively (log-rank p ¼
0.0001). Regarding CAPS, cumulative event-free
survival rates were 97% for CV death/MI and
82% for composite adverse CV events, respectively,
in patients with CAPS 2, and 47% and 4% for
CV death/MI and composite adverse CV events,
respectively, with CAPS 4.Multivariable predictors of events. In multivariable
analysis, coronary CTA characteristics that were
signiﬁcant by univariable analysis were corrected for
baseline characteristics. Multivariable predictors of
events, calculated with the 2 models (UCT and
CAPS), are reported in Table 4. Signiﬁcant inde-
pendent coronary CTA predictors of events were
UCT 1, 2, and 3 and CAPS 2 and 4. The HRs were
particularly high for UCT 2 and 3 (7.78 and 10.14,
respectively, for CV death/MI, and 5.42 and 12.13,
respectively, for combined adverse CV events) and
for CAPS 2 and 4 (2.98 and 15.28, respectively, for
CV death/MI, and 6.76 and 7.92, respectively, for
combined adverse CV events).
Incremental prognostic value of coronary CTA. The
incremental prognostic value of coronary CTA
among post-CABG patients is assessed with the
AUC and the NRI for the model with and without
the variable of interest (UCT or CAPS), adjusted
for age, sex, smoking, hypercholesterolemia, hy-
pertension, diabetes, and family history of CAD.
For the primary endpoint (CV death/MI), there is
a statistically signiﬁcant difference between the
Figure 2. CAPS Survival Analysis
Kaplan-Meier curves for CV death/MI (A) and for composite adverse CV events (B) in patients with coronary artery protection score (CAPS)
1 to 4. Abbreviations as in Figure 1.
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586AUC for both UCT and CAPS (p < 0.01). NRI
was computed to evaluate the improvement of
the new models. Moreover, we compared UCT
and CAPS, showing that the UCT index adds
more prognostic value in the model in compari-
son to the CAPS index for the composite adverse
CV events (NRI ¼ 0.7976 [95% conﬁdence in-
terval: 0.938 to 0.657] p < 0.0001).
D I SCUSS ION
The prognostic value of coronary CTA as a
noninvasive tool has been demonstrated in patients
with suspected CAD and in those without a history
of revascularization (4,6,12–14). On the other hand,
the usefulness of risk stratiﬁcation of CABG pa-
tients on the basis of graft anatomy has been shown
with ICA. Liao et al. (9) developed an ICA prog-
nostic model for patients with previous CABG
showing that the graft index and number of un-
protected coronary territories predicted all-cause
mortality. However, the possibility of translating
this model to coronary CTA is less certain. Indeed,
CABG patients typically have severe native CADand diffuse coronary calciﬁcations that may hamper
the diagnostic accuracy of coronary CTA (15,16).
This may negatively affect the ability to determine
prognosis and may limit coronary CTA clinical
utility in the CABG population. In fact, when
assessing the prognosis of patients after CABG
surgery, it is essential to complete the anatomic data
on bypass grafts with those on native coronary ar-
teries (9). For this reason, in the present study, we
used 2 scores to capture anatomic information
regarding both bypass grafts and native coronary
arteries, as suggested by the literature (7,8).
There are only 2 previous studies assessing the
prognostic utility of coronary CTA in CABG pa-
tients. One by Small et al. (8) classiﬁed 657 patients
using UCT and CAPS with a mean follow-up of 20
months and another by Chow et al. (7) that enrolled
250 patients who were classiﬁed with the UCT
score and were followed for 20 months. In com-
parison to them, our study had a longer follow-up in
a larger group of CABG patients. The main ﬁnd-
ings of the present study are that coronary CTA is
able to provide long-term prognostic information in
CABG patients and may predict CV death/MI.
Table 4. Multivariable Signiﬁcant Predictors of Events
Combined Adverse CV Events
HR (95% CI) p Value
CV Death/MI
HR (95% CI) p Value
Model 1: UCT
Age 0.99 (0.97–1.01) 0.59 1.00 (0.97–1.04) 0.63
Male 0.79 (0.51–1.22) 0.29 0.97 (0.44–2.14) 0.95
Smoking 0.74 (0.51–1.07) 0.11 0.44 (0.23–0.84) 0.012
Dyslipidemia 1.37 (0.94–1.99) 0.03 1.46 (0.79–2.70) 0.21
Diabetes 1.64 (1.15–2.34) 0.005 1.48 (0.84–2.58) 0.16
Hypertension 1.49 (1.02–2.19) 0.03 1.32 (0.69–2.53) 0.38
Family history of CAD 0.68 (0.44–1.06) 0.09 0.57 (0.25–1.27) 0.17
Statins 0.64 (0.45–0.89) 0.008 0.51 (0.29–0.90) 0.02
Nitrates 1.76 (1.38–2.25) <0.0001 2.56 (1.67–3.9) <0.0001
Positive stress test 2.38 (1.23–4.58) 0.009 2.17 (0.73–6.40) 0.15
UCT 1 2.42 (1.65–3.55) <0.0001 1.42 (0.71–2.83) 0.31
UCT 2 5.42 (3.57–8.24) <0.0001 7.78 (3.90–15.51) <0.0001
UCT 3 12.13 (4.57–32.22) <0.0001 10.14 (2.66–38.52) <0.0007
Model 2: CAPS
Age 0.99 (0.97–1.01) 0.61 1.00 (0.97–1.04) 0.63
Male 0.86 (0.56–1.32) 0.49 0.94 (0.42–2.06) 0.88
Smoking 0.74 (0.52–1.06) 0.11 0.44 (0.24–0.82) 0.009
Dyslipidemia 1.34 (0.93–1.94) 0.11 1.44 (0.78–2.65) 0.24
Diabetes 1.36 (0.95–1.94) 0.08 1.41 (0.81–2.46) 0.22
Hypertension 1.47 (1.00–2.17) 0.04 1.30 (0.68–2.48) 0.42
Family history of CAD 0.77 (0.50–1.19) 0.24 0.56 (0.25–1.25) 0.15
Statins 0.70 (0.50–0.98) 0.04 0.57 (0.33–0.99) 0.04
Nitrates 2.12 (1.55–2.9) <0.0001 2.37 (1.55–3.64) <0.0001
Positive stress test 2.26 (1.19–4.30) 0.01 2.22 (0.75–6.60) 0.14
CAPS 2 6.76 (3.56–12.80) <0.0001 2.98 (0.84–10.56) 0.08
CAPS 3 2.29 (1.32–3.94) 0.002 2.71 (0.92–7.93) 0.06
CAPS 4 7.92 (4.46–14.05) <0.0001 15.28 (5.19–44.97) <0.0001
Abbreviations as in Tables 1 and 3.
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587Speciﬁcally, we found that the best parameter to
predict cardiac events is the number of unprotected
territories. This ﬁnding was conﬁrmed by both
UCT and CAPS assessment. Indeed, evaluating the
UCT score, we found that the risk of both CV
death/MI and combined adverse CV events pro-
gressively increases from UCT 1 to UCT 3 at
univariable analysis (HR for UCT 1: 1.24 and 2.75
for CV death/MI and combined adverse CV events,
respectively, and HR for UCT 3: 10.1 and 8.47 for
CV death/MI and combined adverse CV events,
respectively). Moreover, high-grade UCTs were also
demonstrated to be strong multivariable indepen-
dent predictors of CV death/MI, exhibiting a HR of
7.7 and 10.1 for UCT 2 and 3, respectively. TheKaplan-Meier survival curves conﬁrmed the
important prognostic value of UCT 2 and 3, with
event-free survival rates for CV death/MI of 53%
for UCT 2 and 29% for UCT 3 at 73-month
follow-up. Thus, the number of UCTs allowed
the identiﬁcation of patient subgroups with pro-
gressively worse outcomes. These ﬁndings are in
agreement with the study by Chow et al. (7)
demonstrating that UCTs were predictors of ma-
jor adverse cardiac events at 20-month follow-up.
Using CAPS, we were able to conﬁrm the UCT
ﬁndings. Indeed, the CAPS value associated with
higher risk for CABG patients was CAPS 4, which
included 2 scores corresponding to at least 2 UCTs.
Notably, patients with CAPS 4 showed the highest
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588HRs for CV death/MI at both univariable (24.1)
and multivariable (15.2) analysis. Moreover, pa-
tients with CAPS 2, which includes also people
with 2 unprotected territories (patients with 2-vessel
disease and 1 protected territory, and 2-vessel dis-
ease and 0 protected territories) had higher HR
for both CV death/MI and combined adverse
CV events in comparison with patients with CAPS
3, which includes people with not more than 1
unprotected territory (patients with 3-vessel disease
and 3 protected territories, and 3-vessel disease and
2 protected territories). The 73-month event-free
survival rates by Kaplan-Meier curves with respect
to CV death/MI were 97% for CAPS 1 and 48% for
CAPS 4. Therefore, CAPS analysis showed that the
number of unprotected territories seems to be the
best predictor of cardiac events in CABG patients,
as compared with the number of native coronary
arteries exhibiting signiﬁcant CAD alone. So, cor-
onary CTA–derived UCTs seems to be a feasible
and simple score to adopt in clinical practice and
therefore may be used as a reliable method with
prognostic value for risk stratiﬁcation of CABG
patients. Moreover, although the analysis of AUC,
NRI, and integrated discrimination improvement to
assess the incremental prognostic value of coronary
CTA showed that both UCT and CAPS add a
statistically signiﬁcant improvement in the model
adjusted for age, sex, smoking, hypercholesterole-
mia, hypertension, diabetes, and family history of
CAD, the comparison between UCT and CAPS
demonstrated that the UCT index adds a greater
improvement in the model. Finally, concerning the
potential hazard of radiation exposure, it should
be noted that recent studies demonstrated highaccuracy in the evaluation of CABG, native post-
anastomotic coronary arteries, and nongrafted
coronaries, even when low-radiation-exposure
techniques were used (2).
Study limitations. First, this is a relatively small,
single-center study evaluating mainly Caucasian
patients. Thus, its results may not necessarily
reﬂect the patient population of other centers or
countries. Second, despite the percentage of pa-
tients with complete follow-up being remarkably
high (98%), we recognize that incomplete follow-up
may result in underreporting of cardiac events.
Third, although an independent prognostic role of
coronary CTA anatomic evaluation was demon-
strated by our study, additional information about
the amount and distribution of regional ischemia
by means of imaging stress testing would have
been important to assess the potential comple-
mentary prognostic value of these diagnostic
approaches.CONCLUS IONS
The identiﬁcation by means of coronary CTA of
CABG patients with 2 or more UCTs, who as
demonstrated by our long-term follow-up study are
at high risk for cardiac events, is of clinical rele-
vance, suggesting that a subgroup of them may
require closer clinical surveillance eventually associ-
ated with timely treatment.
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